Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets open weak on Asian cues
Tue, 6 Sep 09:30 am

Most Asian stock markets have opened the day on a weak note. Stock markets in Hong Kong (down 1.1%), Singapore (down 1.1%), Japan (down 1.3%) and Taiwan (down 1.5%) are leading the pack of losers. However, markets in Indonesia (up 0.2%) are trading firm. The Indian stock markets have opened the day on a weak note. Banking and technology stocks are leading the losses. However, stocks in the consumer durable and auto space are trading firm.

The BSE-Sensex is trading lower by around 58 points (0.3%), while the NSE-Nifty is down by around 20 points (0.4%). However, mid cap and small cap stocks are trading in the green, with the BSE Mid Cap and BSE Small Cap indices up by 0.3% and 0.1% respectively. The rupee is trading at 46.13 to the US dollar.

Auto stocks have opened the day on a strong note with Tata Motors and Maruti Suzuki leading the gains. Mahindra & Mahindra (M&M) has hiked prices for the entire range of products including Scorpio, Xylo and Bolero by 2%. The increase in the prices is a result of the rising raw material costs. The management has shown concerns over the rising costs. In January 2011, M&M raised the prices by 1.5% which was later followed by another similar hike in April 2011. This hike is the third in the same calendar year. On the sales front, the management said that they were cautiously optimistic. The company increased its sales by 31% YoY in domestic sales in August 2011. Similarly, in July 2011, it witnessed an increase of 42% YoY.

Pharma Stocks have open the day on a mixed note with Sun Pharma and Dr Reddy's Laboratories trading in the red. However, Aurobindo Pharma and Orchid Chemicals are trading firm. Indian pharma major Ranbaxy Laboratories has launched the first generic version of Nexium in Britain. Nexium is AstraZeneca Plc's heartburn and ulcer drug. Ranbaxy is offering 20 mg and 40 mg tablets of esomeprazole, which is the generic name for Nexium, through pharmacies, retail and wholesale stores. In Britain, the sales of Nexium aggregate to about 60 m British Pounds (US$ 97 m) a year. The entry of Ranbaxy's generic version is going to escalate pressure on European sales of the top-selling medicine.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets open weak on Asian cues". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.